The impact of the Oncotype DX® Breast Cancer Assay on the patient treatment journey

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the impact of the Oncotype DX® Breast Cancer Assay, a multigene assay that stratifies patients into risk groups that are associated with distant recurrence and response to adjuvant chemotherapy, on treatment decisions for patients with early stage breast cancer.

This content is supported by Genomic Health, Inc.

Year of Production:
Running Time:


Comments are closed.